Individuals with early cognitive impairment, regardless of changes in Aβ and/or tau biomarkers of AD, develop brain capillary damage and disruption of the hippocampal BBB, indicating that BBB disruption is an early biomarker of human cognitive dysfunction independent of Aβ and tau (Nation et al., 2019). Here, MAPT is linked to Alzheimer disease.